(Q38959006)

English

The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells

scientific article published on 18 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells (English)

1 reference

Europe PubMed Central

8 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Douglas M. Noonan

8

1 reference

Europe PubMed Central

8 September 2017

10

1 reference

Europe PubMed Central

8 September 2017

Francesca Reggiani

object named as

Francesca Reggiani

2

0 references

Stefania Orecchioni

object named as

Stefania Orecchioni

1

0 references

Francesco Bertolini

object named as

Francesco Bertolini

11

0 references

Patrizia Mancuso

4

object named as

Patrizia Mancuso

1 reference

Europe PubMed Central

8 September 2017

Angelica Calleri

5

object named as

Angelica Calleri

1 reference

Europe PubMed Central

8 September 2017

Giuliana Gregato

6

object named as

Giuliana Gregato

1 reference

Europe PubMed Central

8 September 2017

Valentina Labanca

7

object named as

Valentina Labanca

1 reference

Europe PubMed Central

8 September 2017

Giovanna Talarico

3

object named as

Giovanna Talarico

1 reference

Europe PubMed Central

8 September 2017

Katiuscia Dallaglio

9

object named as

Katiuscia Dallaglio

1 reference

Europe PubMed Central

8 September 2017

language of work or name

0 references

publication date

18 September 2014

1 reference

Europe PubMed Central

8 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

8 September 2017

136

1 reference

Europe PubMed Central

8 September 2017

6

1 reference

Europe PubMed Central

8 September 2017

E534-44

1 reference

Europe PubMed Central

8 September 2017

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Understanding the benefit of metformin use in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

The effect of metformin on apoptosis in a breast cancer presurgical trial.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin inhibits skin tumor promotion in overweight and obese mice

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin targets ovarian cancer stem cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin is synthetically lethal with glucose withdrawal in cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin in obesity, cancer and aging: addressing controversies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin--mode of action and clinical implications for diabetes and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Potential applications for biguanides in oncology

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Phenformin as prophylaxis and therapy in breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Implanted adipose progenitor cells as physicochemical regulators of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Human adipose tissue-derived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Paradoxic effects of metformin on endothelial cells and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Angiogenesis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

AMPK-independent down-regulation of cFLIP and sensitization to TRAIL-induced apoptosis by AMPK activators

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Metformin improves healthspan and lifespan in mice

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Lactic acidosis induced by metformin: incidence, management and prevention

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Molecular pathways: preclinical models and clinical trials with metformin in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29193

21 January 2018

Identifiers

10.1002/IJC.29193

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38959006&oldid=1835219169"